MAPK8 and pachyonychia congenita: All cell lines were treated with JNK inhibitors addressing different backgrounds: SP600125 is a commonly used reversible ATP-competitive pan-JNK inhibitor (29) which effectiveness in PC was shown by us and others (18, 30).